Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 2492 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

KYOWA Reports Nine Months Fiscal 2008 Results

Consolidated operating income was JPY42.6 billion (up 31.8%), recurring income was JPY43.2 billion (up 32.1%), and net income was JPY10.4 billion (down 56.5%). Net income was affected by

Altus plans to cut 75% of its workforce

To conserve capital resources, Altus will discontinue its Trizytek program activities and focus on the advancement of the company’s breakthrough, long-acting, recombinant human growth hormone candidate, ALTU-238, as